High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program-Reference-Cited by-同舟云学术

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

Published:2009-01 Issue:2 Volume:144 Page:169-175
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Mikhael Joseph R.,Belch Andrew R.,Prince H. Miles,Lucio Maria Nambo,Maiolino Angelo,Corso Alessandro,Petrucci Maria Teresa,Musto Pellegrino,Komarnicki Mieczyslaw,Stewart A. Keith

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07409.x/fullpdf

Reference24 articles.

1. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Bladé;British Journal of Haematology,1998

2. Recent major improvement in long-term survival of younger patients with multiple myeloma;Brenner;Blood,2007

3. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;New England Journal of Medicine,2003

4. State of the art therapy in multiple myeloma and future perspectives;Denz;European Journal of Cancer,2006

5. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma;Fenk;Leukemia and Lymphoma,2007

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12

2. Recent advances in the treatment and prevention of peripheral neuropathy after multiple myeloma treatment;Ibrain;2023-09-06

3. Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study;Clinical Lymphoma Myeloma and Leukemia;2021-10

4. Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma;Protein Expression and Purification;2021-09

5. “Direct to Drug” screening as a precision medicine tool in multiple myeloma;Blood Cancer Journal;2020-05